MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, FDMT had -$28,604K decrease in cash & cash equivalents over the period. -$46,407K in free cash flow.

Cash Flow Overview

Change in Cash
-$28,604K
Free Cash flow
-$46,407K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-56,876 -102,630
Stock-based compensation expense
4,519 11,944
Change in fair value of derivative liability
11 -76
Depreciation and amortization
1,261 2,217
Amortization of right-of-use assets
742 1,425
Net accretion of discount on marketable securities
1,154 2,433
Prepaid expenses and other current assets
-2,748 7
Other assets
-10 5,129
Accounts payable
-1,837 4,314
Accrued and other liabilities
4,982 798
Deferred revenue
-90 -29
Operating lease liabilities
-814 -1,529
Net cash used in operating activities
-46,498 -91,135
Purchase of marketable securities
15,241 249,480
Maturities of marketable securities
32,928 268,273
Acquisition of property and equipment
-91 697
Net cash provided by (used in) investing activities
17,778 18,096
Issuance of common stock upon exercise of stock options and warrants
116 2
Issuance of common stock - 2020 espp
0 860
Net cash provided by financing activities
116 862
Net decrease in cash and cash equivalents
-28,604 -72,177
Cash and cash equivalents at beginning of period
149,336 -
Cash and cash equivalents at end of period
48,555 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics, Inc. (FDMT)